Innovative at our Core
Alera Bio is headquartered in Chicago and is a privately held biopharmaceutical company formed in 2025. Alera Bio was founded with a singular goal: to develop transformative therapies to improve the lives of patients suffering from devastating neurological deficits.
​
Led by a team of experienced biotech professionals, we specialize in pioneering treatments for rare diseases that impact critical systems in the body, including thyroid hormone signaling and neurotransmitter balance.
​
Our company is at the forefront of biomedical innovation, developing therapies that target the devastating neurological effects of diseases like MCT-8 deficiency, a rare and devastating condition that disrupts thyroid hormone transport and neurodevelopment.
With a strong foundation in cutting-edge scientific research, we aim to bring new hope to patients and families affected by genetic disorders and neurodevelopmental challenges.
Our Approach
At Alera Bio, we are committed to precision medicine and science-driven innovation. Our approach to drug development combines deep biochemical expertise with a patient-centric focus.​
​
We continually seek new and groundbreaking approaches to address the challenges faced by patients and healthcare providers. By pushing the boundaries of scientific discovery, we aim to bring about transformative changes in the treatment and management of MCT-8 deficiency.
Our Concentration
Restoring Biological Function
We target the underlying molecular pathways disrupted in diseases such as MCT-8 deficiency, aiming to restore thyroid hormone transport, optimize neurotransmitter function, and correct metabolic imbalances.
Advanced Therapeutic Solutions
By utilizing novel technologies and rigorous research, we are developing therapies that not only address the symptoms of these rare diseases but also correct the biochemical roots that cause them.
Comprehensive Drug Development
Our drug development process is thorough and patient-focused. We partner with leading research institutions to ensure that our treatments are based on the best available science and offer tangible benefits to patients.
Get Involved
We're All In...
As we continue our journey to transform the landscape of rare disease treatment, we invite stakeholders from the scientific, healthcare, investment and patient advocacy communities to join us.
Whether you’re interested in collaborating with us on research, participating in clinical trials, want to invest in the future development, or simply learning more about our progress, we welcome engagement from those passionate about advancing science and improving patient care. Click the button below to receive updates.